BLOOD RESEARCH

  • 제53권4호
  • /
  • Pages.294-298
  • /
  • 2018
  • /
  • 2287-979X(pISSN)
  • /
  • 2288-0011(eISSN)
대한혈액학회 (The Korean Society of Hematology)
권호 표지
DOI QR코드

DOI QR Code

Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype

  • Arandi, Nargess (Hematology Research Center, Shiraz University of Medical Sciences) ;
  • Ramzi, Mani (Hematology Research Center, Shiraz University of Medical Sciences) ;
  • Safaei, Fatemeh (Department of Pathology, School of Medicine, Shiraz University of Medical Sciences) ;
  • Monabati, Ahmad (Department of Pathology, School of Medicine, Shiraz University of Medical Sciences)
  • 투고 : 2018.06.19
  • 심사 : 2018.07.17
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

Background Production of immunosuppressive enzymes such as indoleamine 2,3-dioxygenase (IDO) is one of the strategies employed by hematologic malignancies, including acute myeloid leukemia (AML), to circumvent immune surveillance. Moreover, IDO has the ability to convert $CD4^+CD25^-$ conventional T cells into regulatory T cells (Tregs). In this study, we evaluated the expression of IDO in cytogenetically normal acute myeloid leukemia (CN-AML) patients and its correlation with the Treg marker, FOXP3, as well as clinical and laboratory parameters. Methods Thirty-seven newly diagnosed CN-AML patients were enrolled in our study along with 22 healthy individuals. The expression of the IDO and FOXP3 genes was analyzed by SYBR Green real-time PCR. Results Both IDO and FOXP3 were highly upregulated in CN-AML patients compared to control groups (P=0.004 and P=0.031, respectively). A positive correlation was observed between IDO and FOXP3 expression among AML patients (r=0.512, P=0.001). Expression of IDO and FOXP3 showed no significant correlation with laboratory parameters such as white blood cell and platelet counts, hemoglobin levels, bone marrow blast percentage, gender, and FLT3 mutation status (P>0.05). Conclusion Higher IDO expression in CN-AML patients may be associated with an increased Treg phenotype which may promote disease progression and lead to poor prognosis of CN-AML patients.

키워드

과제정보

연구 과제 주관 기관 : Shiraz University of Medical Sciences

참고문헌

  1. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-73. https://doi.org/10.1016/S0167-5699(99)01520-0
  2. Corm S, Berthon C, Imbenotte M, et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk Res 2009;33:490-4. https://doi.org/10.1016/j.leukres.2008.06.014
  3. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196:459-68. https://doi.org/10.1084/jem.20020121
  4. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297:1867-70. https://doi.org/10.1126/science.1073514
  5. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-21. https://doi.org/10.1182/blood-2003-11-3909
  6. Godin-Ethier J, Pelletier S, Hanafi LA, et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol 2009;183:7752-60. https://doi.org/10.4049/jimmunol.0901004
  7. Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005;11:6030-9. https://doi.org/10.1158/1078-0432.CCR-04-2671
  8. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006;95:1555-61. https://doi.org/10.1038/sj.bjc.6603477
  9. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12:1144-51. https://doi.org/10.1158/1078-0432.CCR-05-1966
  10. Teague RM, Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer 2013;1:13. https://doi.org/10.1186/2051-1426-1-13
  11. Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol Hematol 2016;103:62-77. https://doi.org/10.1016/j.critrevonc.2016.04.020
  12. Curti A, Aluigi M, Pandolfi S, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007;21:353-5. https://doi.org/10.1038/sj.leu.2404485
  13. Fukuno K, Hara T, Tsurumi H, et al. Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediaterisk cytogenetics. Leuk Lymphoma 2015;56:1398-405. https://doi.org/10.3109/10428194.2014.953150
  14. Chamuleau ME, van de Loosdrecht AA, Hess CJ, et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008;93:1894-8. https://doi.org/10.3324/haematol.13112
  15. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumorinduced tolerance. J Clin Invest 2007;117:1147-54. https://doi.org/10.1172/JCI31178
  16. Lin TL, Smith BD. Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia. Am J Med Sci 2011;341:404-8. https://doi.org/10.1097/MAJ.0b013e318201109d
  17. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-48. https://doi.org/10.1182/blood-2006-06-001149
  18. Wang M, Yang C, Zhang L, Schaar DG. Molecular mutations and their cooccurrences in cytogenetically normal acute myeloid leukemia. Stem Cells Int 2017;2017:6962379.
  19. Mitelman F. ISCN 1995: An International System for Human Cytogenomic Nomenclature (2016). Basel, Switzerland: S. Karger, 1995.
  20. Folgiero V, Goffredo BM, Filippini P, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget 2014;5:2052-64.
  21. El Kholy NM, Sallam MM, Ahmed MB, et al. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells. Med Oncol 2011;28:270-8. https://doi.org/10.1007/s12032-010-9459-6
  22. Curti A, Pandolfi S, Valzasina B, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007;109:2871-7. https://doi.org/10.1182/blood-2006-07-036863
  23. Curti A, Trabanelli S, Onofri C, et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 2010;95:2022-30. https://doi.org/10.3324/haematol.2010.025924
  24. Wang XF, Wang HS, Wang H, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol 2014;289:42-8. https://doi.org/10.1016/j.cellimm.2014.02.005
  25. Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014;3:e957994. https://doi.org/10.4161/21624011.2014.957994
  26. Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 2015;3:51. https://doi.org/10.1186/s40425-015-0094-9

피인용 문헌

  1. A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy vol.10, pp.None, 2018, https://doi.org/10.3389/fonc.2020.00262
  2. Checkpoint inhibitors in AML: are we there yet? vol.188, pp.1, 2020, https://doi.org/10.1111/bjh.16358
  3. Alterations of T-cell-mediated immunity in acute myeloid leukemia vol.39, pp.18, 2020, https://doi.org/10.1038/s41388-020-1239-y
  4. Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review vol.27, pp.28, 2020, https://doi.org/10.2174/0929867326666191004164041
  5. Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review vol.12, pp.None, 2018, https://doi.org/10.3389/fimmu.2021.651687
  6. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes vol.11, pp.None, 2021, https://doi.org/10.3389/fonc.2021.624742
  7. Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies vol.11, pp.None, 2018, https://doi.org/10.3389/fonc.2021.674720
  8. Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias vol.13, pp.6, 2018, https://doi.org/10.3390/cancers13061203
  9. Redirecting the Immune Microenvironment in Acute Myeloid Leukemia vol.13, pp.6, 2018, https://doi.org/10.3390/cancers13061423
  10. The guanidine thiocyanate‐high EDTA method for total microbial RNA extraction from severely heavy metal‐contaminated soils vol.14, pp.2, 2018, https://doi.org/10.1111/1751-7915.13615
  11. Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation from a Common Precursor vol.207, pp.6, 2018, https://doi.org/10.4049/jimmunol.2100023